Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Elagolix is a prescription gonadotropin-releasing hormone receptor antagonist sold in the United States as Orilissa. It is approved for management of moderate to severe pain associated with endometriosis. Tablets come in 150 mg and 200 mg strengths, with treatment duration limited according to dose and liver function.
read more about elagolix ...Elagolix competitively binds gonadotropin-releasing hormone receptors in the pituitary gland and reduces GnRH signaling. This lowers luteinizing hormone and follicle-stimulating hormone secretion, followed by dose-dependent reductions in estradiol and progesterone concentrations.
Elagolix is used for moderate to severe pain associated with endometriosis. Pregnancy is excluded before treatment unless therapy begins within seven days from the onset of menses. It is contraindicated during pregnancy, in known osteoporosis, in severe liver impairment, and with certain OATP1B1 inhibitors.
With normal liver function or mild liver impairment, 150 mg once daily can continue for up to 24 months, while 200 mg twice daily is limited to six months. Moderate liver impairment uses 150 mg once daily for up to six months. Tablets are taken at about the same time each day with or without food.
Elagolix causes dose-dependent bone mineral density loss that can be only partly reversible after treatment ends. Other serious concerns include reduced recognition of pregnancy due menstrual changes, suicidal thoughts or behavior, worsening mood disorders, liver enzyme elevations, and interactions with hormonal contraceptives. Nonhormonal contraception is used during treatment and for 28 days afterward.
Elagolix treats moderate to severe pain associated with endometriosis.
The 150 mg once-daily regimen can continue for up to 24 months with normal or mildly impaired liver function.
No. Pregnancy is a contraindication due the risk of early pregnancy loss.
Yes. Bone mineral density decreases with dose and treatment duration and recovery after stopping can be incomplete.
Elagolix: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a618044.html. Date Accessed September 29, 2026.
ORILISSA (Elagolix) Tablets, for Oral Use. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a86757b3-09c5-fd3b-1223-244e94f50a66. Date Accessed September 29, 2026.
ORILISSA (Elagolix) Tablets, for Oral Use, 150 mg and 200 mg, Full Prescribing Information with Medication Guide. https://www.rxabbvie.com/pdf/orilissa_pi.pdf. Date Accessed September 29, 2026.
ORILISSA Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210450s009lbl.pdf. Date Accessed September 29, 2026.
Understanding Endometriosis: From Symptoms to Treatment. https://www.fda.gov/consumers/knowledge-and-news-women-owh-blog/understanding-endometriosis-symptoms-treatment. Date Accessed September 29, 2026.